Please provide your email address to receive an email when new articles are posted on . Long-acting injectable paliperidone use was associated with significant improvement in clinical and functional ...
PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today ...
On May 5, 2020, Manson J. of the Federal Court issued the second decision on the merits under the amended Patented Medicines (Notice of Compliance Regulations). The Court upheld the validity of ...
The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Paliperidone 3 mg, 6 mg, 9 mg; extended-release tabs. Paliperidone is the major active metabolite of risperidone. Although the mechanism of action of this atypical antipsychotic is unknown, the ...
Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...
Janssen, L.P.'s INVEGA Approved By FDA As New Treatment For Schizophrenia TITUSVILLE, N.J., Dec. 20 /PRNewswire/ -- First Oral Extended Release Medication to Treat Schizophrenia. The U.S. Food and ...
UZEDY ® (1-month and 2-month subcutaneous risperidone for treatment of schizophrenia), is the first product based on Medincell's long-acting injection technology that reached commercial stage. UZEDY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results